Transdermal delivery of cannabidiol
Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.
1. A pharmaceutical composition comprising cannabidiol (CBD), in a dosage form for transdermal delivery wherein the pharmaceutical composition comprises:
a concentration of CBD selected from the group consisting of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, and about 15% w/w;
about 5% to about 20% w/w of a solvent comprising propylene glycol;
about 1% to about 20% w/w of a penetration enhancer comprising oleic acid
about 2% to about 15% w/w of at least one suspending agent comprising silicon dioxide; and
about 50% to about 80% w/w of a silicone pressure sensitive adhesive,
wherein the pH of the composition is maintained at approximately 4.0 to 8.0,
herein the pharmaceutical composition is in the form of a transdermal matrix patch, further wherein the pharmaceutical composition provides a constant rate of delivery of the active components of the transdermal matrix patch in a therapeutic range in a patient over 7 days.
2. The pharmaceutical composition of claim 1 further comprising carriers or ingredients selected from the group consisting of gelling agents, polymers, emollients, skin irritation reducing agents, buffering agents, pH stabilizers, solubilizers, dispersing agents, stabilizers, plasticizers, surfactants, antioxidants, oxidants, and combinations thereof.
3. The pharmaceutical composition of claim 1 further comprising carriers or ingredients selected from the group consisting of gelling agents, polymers, emollients, skin irritation reducing agents, buffering agents, pH stabilizers, solubilizers, dispersing agents, stabilizers, plasticizers, surfactants, antioxidants, oxidants, and combinations thereof in the range of 0.01%-95% w/w or w/v.
4. The pharmaceutical composition of claim 1 which is formulated as a transdermal matrix patch formulation which can be administered in a dosage regimen selected from the group consisting of once in a week, once in about 8 to about 13 days, once in two weeks, once in about 15 days to about 30 days.
5. The pharmaceutical composition of claim 1 wherein said CBD or derivative thereof is produced by a synthetic route.
6. A method for the treatment of pain and/or inflammation comprising: selecting a patient in need of treatment of pain and/or inflammation; topically applying a pharmaceutical composition comprising cannabidiol, the free base thereof, salts thereof, isomers thereof, amorphous forms thereof, crystalline forms thereof, co-crystalline forms thereof, prodrugs thereof, analogs thereof, derivatives thereof, synthetic forms thereof, biosynthetic forms thereof, active metabolites thereof, alone or in combinations thereof, in a dosage form for transdermal delivery.
7. The method of claim 6 , wherein the topical application of a transdermal patch for the treatment of pain and/or inflammation is selected from the group consisting of once in a day, once in two days, once in three days, once in four days, once in five days, once in six days, once in a week, once in ten days.
8. The method of claim 6 further providing a constant rate of delivery of the active components of the transdermal patch over a time period.
9. The method of claim 6 further providing a steady absorption rates of the active components of the transdermal patch over a time period.
10. The method of claim 6 further achieving a constant blood serum levels of the active components of the transdermal patch over a time period.
11. The method of claim 6 further achieving a reduced variability in dosage of the active components of the transdermal patches over a time period.
12. The method of claim 6 further providing a plasma concentration of the active components of the transdermal patch in a therapeutic range over a period of time.
13. The method of claim 6 wherein the topical application of a transdermal patch is for the treatment of pain and/or inflammation of indications selected from the group consisting of headaches, migraine, tension headaches, cluster headaches, acute pain, chronic pain, neuropathic pain, nociceptive pain, central pain, inflammatory pain, fibromyalgia, drug-induced neuropathic pain, causalgia, complex regional pain syndrome types I and II, and reflex sympathetic dystrophy (RSDS), pain and wasting associated with AIDS, arthritis and rheumatism, migraines, and muscle spasticity associated with multiple sclerosis and paralysis, Autism Spectrum Disorder (ASD) and Autism Spectrum Disorder (ASD) for Pediatric patients, pain and/or inflammation of patients with liver disease, pain and/or inflammation of patients with kidney disease, pain and/or inflammation for liver cancer patients, treating pain and/or inflammation for kidney cancer patients, pain and/or inflammation for cancer patients, and combinations thereof.